Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.47 |
| ▸ | PGR | P06401 | 7/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824963 | 0.81 | NR3C1 (0.62) | NR3C1PGRNR3C2DRD2HTR2A | |
| SCHEMBL6408229 | 0.78 | NR3C1 (0.42) | NR3C1PGRNR3C2 | |
| SCHEMBL4735535 | 0.77 | NR3C1 (0.53) | NR3C1PGRNR3C2 | |
| SCHEMBL6405688 | 0.77 | NR3C1 (0.43) | NR3C1PGRNR3C2 | |
| SCHEMBL4628515 | 0.77 | NR3C1 (0.45) | NR3C1PGRNR3C2 | |
| SCHEMBL5800333 | 0.76 | NR3C1 (0.73) | NR3C1PGRNR3C2AR | |
| SCHEMBL5800842 | 0.76 | NR3C1 (0.52) | NR3C1PGRNR3C2 | |
| SCHEMBL4822532 | 0.75 | NR3C1 (0.61) | NR3C1PGRNR3C2 | |
| SCHEMBL6169279 | 0.75 | NR3C1 (0.61) | NR3C1PGRNR3C2 | |
| SCHEMBL4628801 | 0.74 | NR3C1 (0.44) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | IL1B, NFKBIA, BBOX1 | NR3C1 1483/4885PGR 3289/4885NR3C2 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.